25-Hydroxyvitamin D: Serum Levels and Oral Administration of Calcifediol in Neonates

Publisher Website
Google Scholar
Abstract
This study was undertaken to measure serum 25 OHD [25-hydroxyvitamin D] levels in normal-term infants and their mothers and to compare these with levels found in premature neonates, infants born to diabetic mothers and newborns of mothers taking anticonvulsant medications; evaluate prospectively the relationship of serum 25 OHD level and early neonatal hypocalcemia in premature infants and neonates born to diabetic mothers; and study the efficacy of oral calcifediol (25-hydroxyvitamin D3 [25 OHD3]) beginning from the 1st day of life in the prevention of early neonatal hyoclcemia in premature infants. The complex interrelationship of multiple factors that affect Ca homeostasis leads frequently to the development of early neonatal hypocalcemia. Derangements in vitamin D metabolism during normal and abnormal pregnancies and in the neonatal period play an important role in the pathogenesis of this disorder.